High expression level of BLCA-4 correlates with poor prognosis in human bladder cancer

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 5, 2012, Pages 422-427

  Zhao, Qian ^a   Shen, Wen Hao ^b   Chen, Zhi Wen ^b   Zhou, Zhan Song ^b   Ji, Hui Xiang ^a,b  

^a KUNMING GENERAL HOSPITAL   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Bladder cancer; Blca 4; Immunohistochemical analysis; Prognosis

Indexed keywords

BLCA 4 PROTEIN, HUMAN; BLCA-4 PROTEIN, HUMAN; NUCLEAR PROTEIN; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; BLADDER TUMOR; CANCER GRADING; CANCER STAGING; CHINA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA; AGED; CHINA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84864294395     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Zhang W, Xiang YB, Liu ZW, Fang RR, Ruan ZX, Sun L, Gao LF, Jin F, Gao YT. Trends analysis of common urologic neoplasm incidence of elderly people in Shanghai, 1973-1999. Ai Zheng 2004; 23: 555-558.
3. Ghoneim MA, Abdel-Latif M, el-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A, el-Baz MA. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 2008; 180: 121-127.
4. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176: 2414-2422.
5. Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ and Bahnson RR. Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996; 56: 1690-1694.
6. Konety BR, Nguyen T-ST, Lavelle JP, Zeidel ML and Getzenberg RH. Expression of BLCA-4, a nuclear matrix protein (NMP) marker in a carcinogen induced model of bladder cancer. J Urol 2000; 163: abstract 597.
7. Murphy WM and Soloway MS. Urothelial dysplasia. J Urol 1982; 127: 849-854.
8. Konety BR, Nguyen TS, Brenes G, Sholder A, Lewis N, Bastacky S, Potter DM, Getzenberg RH. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol 2000; 164: 634-639.
9. Van Le TS, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH. Highly specific urine-based marker of bladder cancer. Urology 2005; 66: 1256-1260.
10. Feng CC, Wang PH, Guan M, Jiang HW, Wen H, Ding Q, Wu Z. Urinary BLCA-4 is Highly Specific for Detection of Bladder Cancer in Chinese Han Population and Is Related to Tumour Invasiveness. Folia Biologica 2011; 57: 242-247.
11. Konety BR, Nguyen TS, Dhir R, Day RS, Becich MJ, Stadler WM, Getzenberg RH. Detection of Bladder Cancer Using a Novel Nuclear Matrix Protein, BLCA-4. Clinical Cancer Research 2000; 6: 2618-2625.
12. Myers-Irvin JM, Van Le TS, Getzenberg RH. Mechanistic Analysis of the Role of BLCA-4 in Bladder Cancer Pathobiology. Cancer Res 2005; 65: 7145-7150.
13. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
14. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol 2004; 5: 341-353.
15. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993; 53: 61-66.
16. Miyake Y, Kodama T, Yamaguchi K. Pro-gastrinreleasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1994; 54: 2136-2140.
17. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998; 79: 502-508.